New developments in atherosclerosis: clinical potential of PCSK9 inhibition
Ilaria Giunzioni, Hagai Tavori Knight Cardiovascular Institute, Center for Preventive kaiser copy stands Cardiology, Oregon Health and Science University, Portland, OR, USA Abstract: Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted 692-amino acid protein that binds surface low-density lipoprotein (LDL) receptor (LDLR) and target